 |
|
|
Paloma Pharmaceuticals has created a library of proprietary small molecule drugs through three generations of de novo computational design, medicinal chemistry and synthesis. Of the 3rd generation analogs tested showing significantly greater activity over previous generations, Palomid 529 was chosen as the candidate molecule for clinical development due to its enhanced inhibition of bFGF and VEGF stimulated endothelial cells, inhibition of cancer cell proliferation, induction of apoptosis, lack of estrogenic activity and performance in a variety of animal models of ocular disease. Palomid 529 has been formulated for specific application to the eye. It is to be given through intravitreal administration to remain in the eye for an extended period of time allowing for long term drug delivery. Paloma is currently in development for cancer and earlier for skin applications of the Palomid series of drugs. Both ocular and cancer clinical trials are expected to begin in 2008.
|
|
| | |
|
|
|
